A Drug-Drug Interaction Study of CYP3A4 Inhibition and Pan-CYP Induction on APX001
Status:
Completed
Trial end date:
2020-03-03
Target enrollment:
Participant gender:
Summary
This is a Phase 1, open-label study to evaluate the drug-drug interaction potential of a
strong CYP3A4 inhibitor (itraconazole) and a pan-CYP inducer (rifampin) on APX001 in two
parallel groups of healthy subjects.